





- 1						ledicine
	ean	ers	ın ı	Lanorat	orv iv	ledicine

DATE:	5 SEPTEMBER 2022			
TO:	Edmonton, North, and Central Zones			
FROM:	DynaLIFE Medical Labs and Alberta Precision Laboratories			
	Update to homocysteine reference intervals and reportable range (only applicable to locations that send testing to DynaLIFE)			

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

Effective September 7, 2022 the method used to measure homocysteine at DynaLIFE will change. This
change is being made to extend the upper reportable limit of homocysteine to provide quantitative
results up to 500 µmol/L. Due to the difference in homocysteine results obtained on the two methods,
the homocysteine reference interval will also change.

Background

- The upper reportable limit for homocysteine on the previous method was 65.0 μmol/L. Samples with homocysteine >65.0 μmol/L were sent to another laboratory to obtain quantitative results, prolonging turnaround time
- Measuring homocysteine on the new method will extend the upper reportable limit for homocysteine from 65.0 µmol/L to 500 µmol/L with dilution
- Homocysteine results differ between the old and new method, requiring a new reference interval

How this will impact you

The reference interval and upper reportable limit for homocysteine will change

Parameter	Previous State	New State
Reference Interval	3.7 – 13.9 µmol/L	3.1 – 10.8 µmol/L
Upper Reportable Limit	65.0 µmol/L	500 μmol/L

Action Required

Be aware of the new homocysteine reference interval and upper reportable limit

Questions/Concerns

DynaLIFE Clinical Chemists, 780-451-3702 ext. 3572, clinical.chemists@dynalife.ca

Approved by

- Dr. Kareena Schnabl, Section Chief, Biochemistry, APL, North Sector
- Dr. Michael Mengel, Medical Director, APL, North Sector
- Dr. Mathew Estey, Director of Clinical Chemistry, DynaLIFE Medical Labs
- Dr. Erene Farag, Provincial Medical Director, DynaLIFE Medical Labs